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Abstract: Although cyclometalated Ir(III) complexes have emerged 
as promising photosensitizers for photodynamic therapy, some key 
drawbacks still hamper clinical translation such as operability in the 
phototherapeutic window and ROS production efficiency and 
selectivity. In this work, we report a cyclometalated Ir(III) complex 
conjugated to a far-red emitting coumarin with highly favourable 
properties for cancer phototherapy. Ir(III)-COUPY was efficiently 
taken up by living HeLa cells and showed no dark cytotoxicity and 
impressive photocytotoxicity indexes after blue (161) and green (85) 
light irradiation, even under hypoxia. Importantly, a clear correlation 
between cell death and intracellular superoxide anion radicals’ 
generation after visible light irradiation was demonstrated. By taking 
advantage of the rich photophysical properties of COUPY 
fluorophores and of the well-stablished anticancer activities of Ir(III) 
complexes, this strategy opens the door to novel fluorescent PDT 
agents with promising applications in theragnosis. 
Cyclometalated iridium(III) complexes[1] have gained attention as 
promising photosensitizers (PS) in photodynamic therapy 
(PDT)[2] since they can generate cytotoxic reactive oxygen 
species (ROS) under light irradiation. While direct energy 
transfer from the PS to the ground state of molecular oxygen in 
Type II PDT yields singlet oxygen (1O2), the photochemical 
pathway Type I is more complex and involves the production of 
several types of ROS.[1c] To date, very few Ir(III)-based PS 
operate in the phototherapeutic window, which represents a 
serious drawback for clinical translation owing to the poor tissue 
penetration and toxicity of high energetic wavelengths which 
inevitably cause off target toxicity. However, the choice of the 
optimal wavelength range will depend on the tumor invasion 
depth since unnecessary deeper tissue penetration could also 
impair PDT potency and damage underlying healthy tissues.[2e] 
Ideally, metal-based PS should also operate under hypoxia[3] 
and exhibit strong photocytotoxicity (e.g., high photocytoxicity 
indexes). This might be a problematic issue in the case of 
cyclometalated Ir(III) complexes due to their inherent high dark 
cytotoxicity and strong dependence of photocytotoxicity with 1O2 
production.[1,4] To address these problems, research efforts have 
been dedicated over the last few years to the development of 
novel PDT agents by combining organic fluorophores and metal 
complexes, either by integrating the chromophore within the 
metal coordination sphere via -conjugated linkers or by simply 
attaching them together through a non--conjugated linker. This 
strategy takes advantage of the rich photophysical properties of 
organic fluorophores and of the well-stablished anticancer 
activities of metal complexes.[1] Examples of this approach 
include boron-dipyrromethene (BODIPY) fluorophores,[5] being 
the conjugation to cyclometalated iridium(III) complexes 
particularly appealing.[6] Conventional coumarins have also been 
conjugated to Ir(III) complexes, either to increase singlet oxygen 
quantum yield[7] or to target mitochondria.[8] 
Fluorophores based on small organic molecules have 
become essential daily tools in bioimaging applications, both in 
basic research and in diagnoses and therapy.[9] Recently, we 
have described a novel class of far-red/NIR-emitting 
fluorophores, nicknamed COUPYs, in which the carbonyl group 
of conventional coumarin 1 (Scheme 1) was replaced with N-
alkylated cyano(4-pyridine)methylene moieties (e.g., compound 
2) to increase the push−pull character of the aromatic system.[10]  
Besides operating within the optical window of biological tissues, 
COUPY dyes exhibit several appealing features, such as 
brightness, high photostability and large Stokes’ shifts.[10] 
 
Scheme 1. (A) Rational design of COUPY fluorophores. (B) Structure of 
cyclometalated iridium(III) complexes. (C) Schematic representation of the 
Ir(III)-COUPY conjugate described in this work. 
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Based on these antecedents, we envisaged COUPY 
fluorophores as promising candidates for developing novel 
fluorescent-PDT agents in combination with highly potent 
cyclometalated Ir(III) anticancer complexes which contain a 2-
quinolinylbenzimidazole N^N ligand (e.g., complex 3).[11] Herein, 
we report for the first time the synthesis and biological 
evaluation of a potential PS agent that combines a 
cyclometalated Ir(III) complex with a representative COUPY dye 
(Scheme 1), and demonstrated a good correlation between cell 
death and superoxide anion radicals’ production, which were 
selectively generated after visible light irradiation. 
The attachment of the Ir(III) complex to the fluorophore was 
carried out through the formation of an amide bond between the 
carboxylic acid function of 4 and the free amino group of 
coumarin 5 (see Scheme 1 and the Supporting Information for 
further details). The expected Ir(III)-COUPY conjugate (6) was 
obtained as a dark purple solid after purification by silica column 
chromatography, and fully characterized by HR ESI-MS and 1H 
and 13C NMR. Conjugate 6 was found completely soluble in 
water, which represents an important improvement with respect 
the metal complex, and stable in cell culture medium (DMEM 
supplemented with 10 % FBS) (Figure S2). 
The photophysical properties of conjugate 6 were studied in 
four solvents of different polarity and compared with those of 
coumarin 2 and Ir(III) complex 3 (Table S1 and Figures 1 and 
S3S9). The most relevant findings are that the Ir(III) complex 
shows strong red phosphorescence (660 nm), whose intensity 
decreases in the conjugate in a solvent dependent manner, 
indicating that competitive excited-state processes take place. 
Regarding the coumarin, it shows strong fluorescence (599-609 
nm), whose intensity and lifetime decreases strongly in the 
conjugate, indicating again the existence of competitive excited-
state processes. Fluorescence of the coumarin can also be 
observed when the Ir(III) complex is selectively photoexcited in 
the conjugate, indicating fast energy transfer from the Ir(III) 
complex to the coumarin moiety. In the presence of oxygen, the 
Ir(III) complex produces singlet oxygen (1O2) in all organic 
solvents but not in PBS. The coumarin is a much worse 
photosensitizer in all solvents, however its 1O2 quantum yield 
increases by one order of magnitude in the conjugate, indicating 
an enhanced intersystem crossing induced by the heavy Ir(III) 
ion, which is consistent with the shortening of its fluorescence 
lifetime. Nevertheless, no singlet oxygen can be observed in 
PBS. Very similar quantum yields are observed when either the 
Ir(III) complex or the coumarin moiety are selectively 
photoexcited in organic solvents in conjugate 6, indicating 
almost 100% efficient singlet-singlet energy transfer from the 
Ir(III) complex to the coumarin. In PBS no 1O2 was observed at 
either excitation wavelength for any of the compounds.  
Besides operability in the phototherapeutic window, good 
photostability is desirable in a PS to allow visualization of the 
tumour for a sufficiently long period. We then evaluated the 
photostability of 6 under green light irradiation and compared it 
with that of three control compounds, the parent coumarin 2, 
Rose Bengal (RB) and meso-tetra(4-sulfonatophenyl)porphyrin 
(TPPS). As shown in Figure 1, conjugate 6 was slightly more 
resistant to photobleaching than RB, which is a commonly used 
PS for studies in biological systems. As expected, TPPS was the 
highest photostable compound. Nevertheless, it is worth noting 
that conjugate 6 was found photostable up to light fluences 



























































Figure 1. Left: Comparison of the normalized absorption (solid lines) and 
fluorescence emission (dotted lines) spectra of the compounds in PBS buffer. 
Right: Fluorescence bleaching of the compounds irradiated with green light. 
The cellular uptake of conjugate 6 was studied in living HeLa 
cells by confocal microscopy by irradiation with a yellow light 
laser (ex = 561 nm). As shown in Figure 2, 6 was efficiently 
taken up by the cells since fluorescent vesicles were clearly 
observed in the cytoplasm of all the examined cells. By contrast, 
coumarin 2 accumulates preferentially in mitochondria and 
nucleoli.[10a] To further investigate the cellular uptake of the 
conjugate, Ir accumulation was quantitatively determined by 
ICP-MS after incubation of HeLa cells with iridium compounds. 
As shown in Table 1, the accumulation of 6 at 37 ºC was slightly 
higher (about 1.6-fold) than that of the parent complex (3), which 
indicates that conjugation to the coumarin has a positive effect 
both on internalization and accumulation. Very interestingly, the 
accumulation of conjugate 6 was not modified when incubation 
was carried out at 4 ºC. By contrast, the amount of cellular Ir 
accumulation was considerably reduced after incubation with 3 
at low temperature, which points to an energy-dependent 
pathway. The overall cellular uptake experiments indicate that 
the internalization pathway of Ir(III)-COUPY conjugate differs 
from that of the two separated moieties since it does not 
accumulate in specific organelles such as mitochondria or 
nucleoli but in the cytoplasm, and enters the cells through an 
energy-independent uptake mechanism. 
 
Figure 2. Comparison of the cellular uptake of Ir(III)-COUPY conjugate 6 and 
coumarin 2. Single confocal planes of HeLa cells incubated with 2 (left) and 6 
(right) for 30 min at 37 
o
C. Scale bar: 10 μm. 






Table 1. Cellular Ir accumulation determined by means of ICP-MS in HeLa 





 cells pmol Ir/10
6
 cells 
 4°C 37°C 4°C 37°C 
Ir(III) complex 3 1.3 ± 0.2 7.6 ± 0.4 6.5 ± 1.0 39.4 ± 2.2 
Ir(III)-COUPY 6 11.6 ± 1.0 12.1 ± 0.7 60.4 ± 5.2 62.8 ± 3.4 
[a] HeLa cells were incubated for 2 h with 5 μM of Ir compounds at 4 °C or 
37 °C. Results are the mean ±SDs from three independent experiments. 
 
The in vitro antitumor activity of 6 was tested in HeLa cells 
first in normoxic conditions (21 % O2). Photocytotoxicity was also 
assessed via irradiation with visible light, either with a dose of 28 
J cm-2 of blue light or with 21 J cm-2 of green light. Such doses of 
blue and green light are typically used in photocytotoxicity 
studies with metallodrugs.[13] The parent compounds (coumarin 
2 and complex 3) were also tested to investigate the effect of 
conjugation. In both cases, the MTT assay was performed after 
72 h of incubation. As shown in Table 2, conjugation between 
the Ir(III) complex and the fluorophore led to a negative effect on 
cytotoxicity since the resulting conjugate was found much less 
cytotoxic. This result is particularly surprising considering the 
higher accumulation of the conjugate compared with the parent 
complex (Table 1). To our delight, visible light irradiation clearly 
improved the antitumor activity of the conjugate, leading to IC50 
values of 2.51 (green) and 1.32 (blue) μM. Furthermore, the low 
dark cytotoxicity of conjugate 6 led to excellent PI values both 
after green (85) and blue (161) light irradiation. The PI of 6 after 
irradiation with biologically-compatible green light is particularly 
impressive when compared with that of complex 3 (85 vs 2.9, 
respectively). Although not investigated in this work, yellow and 
even red light could be used to activate conjugate 6 by taking 
advantage of the absorption spectrum of the coumarin moiety. 
The high photocytotoxicity of coumarin 2 suggests a disruption 
of the mitochondrial function given its preferred accumulation in 
this organelle.[10a]  
Having confirmed a close relationship between visible light 
irradiation and cytotoxicity, we investigated ROS generation 
inside the cells, either in the dark or after irradiation. Although 
the three compounds generate a basal level of intracellular ROS 
in the dark (Figures 3 and S6), a remarkable increase in ROS 
production occurred in the case of conjugate 6 after visible light 
irradiation when compared with parent compounds 2 and 3, 
specially with blue light, which cannot be exclusively attributed to 
a higher accumulation (see ROS quantification of 3 and 6 
normalized to the level of cellular Ir accumulation in Figure 3). 
Overall, these results show a clear correlation between the 
photocytotoxicity of the Ir(III)-COUPY conjugate and intracellular 
ROS generation, which confirms its potential applications as PS 
since the production of ROS is the main mechanism for PDT-
initiated cell death. In order to get more insights into the 
photocytotoxicity of the conjugate, the antiproliferative activity of 
all the compounds was tested under low-oxygen conditions (2 % 
O2). Very interestingly, the cytotoxicity of the compounds was 
similar in both, normoxic and hypoxic conditions (Table 2), which 
makes Ir(III)-COUPY conjugates greatly ideal candidates for the 
treatment of hypoxic tumours. 
  
Table 2. Cytotoxicity of the compounds towards HeLa cells.
[a]
 
 Dark  Green Blue  
 IC50 (M) IC50 (M) PI
[b]











Normox 38.7 ± 4.1 0.34 ± 0.11 114 0.37 ± 0.09 105 












Normox 95.2 ± 6.4 32.7 ± 4.9 2.9 2.02 ± 0.24 47 












Normox 213 ± 14 2.51 ± 0.32 85 1.32 ± 0.09 161 
Hypox 219 ± 6 2.77 ± 0.20 79 1.43 ± 0.11 153 
[a] Cells were treated for 2 h (1 h of incubation, 1 h of irradiation at doses of 28 
J cm
-2
 of blue or 21 J cm
-2
 of green light) followed by 70 h of incubation in 
drug-free medium. Control cells were left in the dark. Cells were cultured 
under normoxia (21 % O2) and hypoxia (2 % O2). Results are the means ±SDs 
from three independent experiments. [b] PI - Phototoxicity index was 
calculated by the following formula: PI (Blue, Green) = IC50 (dark-non-
irradiated cells) / IC50 (irradiated cells; blue, green). 
  
 
Figure 3. Left: Quantification of ROS determined by flow cytometry in HeLa 
cells. Cells were treated with 10 μM of the compounds for 1 h in the dark 
followed by 1 h of irradiation with green (21 J cm
-2
) or blue light (28 J cm
-2
). 
Right: Quantification of ROS normalized to the level of cellular uptake (ng 
Ir/10
6
 cells) of Ir compounds determined at 37 °C. Bars represent the mean 
relative fluorescence intensities coming from CellRox® reagent. Error bars 
were calculated from three independent experiments. 
We then focused on identifying the specific cytotoxic ROS 
involved in cell death. Although cyclometalated Ir(III) complexes 
typically produce 1O2,
[1] many other cytotoxic ROS can also be 
generated through type I photochemical processes such as 
hydrogen peroxide (H2O2), hydroxyl radicals (
OH), superoxide 
anion radicals (O2
), peroxynitrite anion (ONOO), etc.[14] To 
determine the specific ROS generated after treatment with Ir(III)-





COUPY conjugate 6, HeLa cells were previously treated with 
several selective ROS scavengers, including sodium pyruvate 
(H2O2), D-mannitol (
OH), tiron (O2
), sodium azide (1O2) and 
ebselen (ONOO-). As shown in Figures 4 and S11, only the use 
of tiron was able to prevent the intracellular production of ROS, 
which suggested the generation of superoxide anion radicals in 
the cells after visible (blue or green) light irradiation in the 
presence of Ir(III)-COUPY conjugate 6. Very interestingly, 
scavenging studies ruled out the production of other types of 
ROS from conjugate 6, including that of 1O2, which agrees with 
the photophysical studies in PBS. In contrast, neither of the two 
components separately, COUPY 2 and Ir(III) complex 3, led to a 
significant production of ROS in HeLa cells, including O2
 
(Figures S12-S15).  
 
Figure 4. Data analysis for determination of ROS in Hela cells by the flow 
cytometry after the irradiation with green (left) of blue light (right). Cells were 
pre-incubated with specific ROS scavengers and then treated with 6 (1 h in the 
dark followed by 1 h under the irradiation). 
Further confirmation of the generation of superoxide anion 
radical from conjugate 6 was obtained by using a cell-based 
assay for the measurement of O2

status in whole cells.[15] As 
shown in Figure S16, a significant increase of the luminescence 
signal with irradiation time of HeLa cells pre-treated with 6 was 
observed, indicating oxidation of luminol substrate. The 
oxidation of luminol was likely due to the generation of 
superoxide anion radical, as suggests the reduction of the signal 
in the presence of superoxide dismutase (SOD), an enzyme that 
catalyzes O2
 disproportionation reactions to form H2O2 and 
O2.
[16] In addition, the use of dihydrorhodamine 123 (DHR123), a 
non-fluorescent probe that emits green fluorescence after 
reaction with O2
, allowed to confirm the generation of 
superoxide anion radical in cell-free media.[16] As shown in 
Figure S17, conjugate 6 increased fluorescence intensity of 
DHR123 markedly more than the Ir(III) complex 3 and COUPY 2. 
Moreover, that increase was significantly suppressed in the 
presence of SOD and ascorbate (Figure S18), thereby 
confirming the involvement of O2
 in oxidation processes 
leading to the fluorescence signal. Interestingly, SOD did not 
show any effect in the case of COUPY 2, in contrast to 
nonspecific reductant sodium ascorbate, which suggests that 
processes other than O2
 production might be responsible for 
the photo effects of 2. Furthermore, laser flash photolysis 
experiments revealed the production of different transient 
species (Figure S9). Thus, at 570 nm the decay was dominated 
by the lifetime of the coumarin triplet state (3.8 and 0.6 s in the 
absence and presence of oxygen). At 630 nm a longer lived 
transient was observed, whose lifetime decreased strongly in the 
presence of oxygen. We interpret this as a reduced form of the 
Ir(III) complex that is scavenged by oxygen to produce O2
. 
Finally, a third species was observed at 490 nm, whose lifetime 
increased in the presence of oxygen. This is interpreted as the 
cation radical of the coumarin moiety[17] since reoxidation of the 
reduced form of the Ir(III) complex by oxygen prevents 
intramolecular charge recombination. Nevertheless, a complete 
unravelling of the photochemical behaviour of Ir(III)-COUPY 
conjugates requires further experiments and will be published 
elsewhere. To the best of our knowledge, this is the first 
example of selective production of superoxide anion radical from 
a compound based on a cyclometalated Ir(III) complex after 
visible light irradiation in cells.[18] Hence, the covalent attachment 
of the coumarin-based COUPY fluorophore to the metal complex 
not only improves cellular uptake and photocytotoxicity under 
visible light irradiation but also triggers the production of highly 
cytotoxic O2
. 
Finally, to investigate the involvement of superoxide anion 
radicals in cell death, we determined the viability of HeLa cells 
after treatment with conjugate 6 under the irradiating conditions, 
both in the absence and in the presence of tiron. As shown in 
Figure S19, the photocytotoxicity of 6 was completely abolished 
in the cells pre-treated with the ROS scavenger, which confirms 
the active role of O2
 in cell death. Excessive O2
, which is one 
of the most toxic ROS, is known to irreversibly damage cellular 
components by reacting with proteins, DNA and lipids.[19] 
Moreover, disproportionation reactions involving O2

might 
trigger the formation of other highly toxic ROS. 
In summary, we have reported the first example of a novel 
PS agent based on the conjugation of a cyclometalated Ir(III) 
complex to a coumarin-based COUPY fluorophore. Ir(III)-
COUPY conjugate (6) exhibits several interesting features for 
cancer phototherapy such as aqueous solubility, excellent 
cellular uptake and high photocytotoxicity under visible light 
irradiation, both in normoxia and hypoxia, being the PI values 
after blue and green light irradiation particularly appealing owing 
to its low dark cytotoxicity compared with the parent compounds, 
especially with the coumarin. Very importantly, treatment with 6 
generates a specific type I ROS in living cells upon visible light 
irradiation, superoxide anion radicals (O2
), whose production 
has been further confirmed through spectroscopic methods and 
correlated with cell death according to cellular viability 
experiments with tiron scavenger. Moreover, HeLa cells could 
be visualized by confocal microscopy by using a yellow light 
laser owing to the spectroscopic properties of the organic 
fluorophore in Ir(III)-COUPY conjugate. Overall, these properties 
indicate that conjugation between far-red/NIR-emitting COUPY 
coumarins and highly potent cyclometalated Ir(III) complexes 
can be exploited to overcome some of the drawbacks of 
traditional PS such as poor tissue penetration and O2-tension 
dependency,[16,20] leading to fluorescent-PDT agents with 
promising applications in diagnosis and photodynamic therapy 
against hypoxic tumours. Work is in progress in our laboratory to 
develop novel Ir(III)-fluorophore conjugates operating in the 
phototherapeutic window, especially in the far-red and NIR 
region, with the aim of using them in targeted PDT. 
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We report a cyclometalated Ir(III) 
complex conjugated to a far-red 
emitting coumarin fluorophore that 
selectively generates superoxide 
anion radicals in living cells after 
irradiation with visible light, and 
demonstrate a clear correlation 
between the production of type I ROS 
and cell death. This compound 
represents the first example of a novel 
class of fluorescent-PDT agents with 
potential applications in cancer 
phototherapy and diagnosis. 
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